Back To: Home : Featured Technology : Liquid Biopsy

CLICK HERE FOR WHAT'S NEW IN:
 

MD Anderson, Trovagene to study transrenal BRAF mutations in primary, metastatic cancers
February 2013
SHARING OPTIONS:

SAN DIEGO—The University of Texas MD Anderson Cancer Center and Trovagene Inc., a developer of transrenal molecular diagnostics, have entered into a clinical collaboration with to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.  
 
Researchers will use Trovagene's proprietary transrenal DNA (TrDNA) detection technology to evaluate BRAF mutation status in urine as compared to tissue biopsy. The study also calls for monitoring of mutation levels in the urine at planned intervals during and after treatment to assess outcomes including: response rate; stable disease; progression-free survival; and overall survival. Results from patients who receive therapy that reflects their BRAF mutation status (e.g., BRAF inhibitors, MEK inhibitors) will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status.  
 
According to recent estimates, BRAF mutations are present in more than 20 percent of all cancers, and in 40 percent and 43 percent of all thyroid and skin cancer samples, respectively. Several targeted therapies for BRAF-mutated melanomas are already on the market and in development, including BRAF inhibitors vemurafenib (Zelboraf) and dabrafenib; and trametinib, a MEK inhibitor.  
 
"One of the potential benefits of TrDNA would be its utility as a systemic, liquid biopsy, providing real-time information that may help guide targeted therapy decisions, and then help clinicians more easily monitor a patient's therapeutic response and disease state," said Dr. Filip Janku, principal investigator for the study at MD Anderson. "A urine-based assay that reliably and cost-effectively detects mutations would be extremely useful as an aid in personalized medicine."  
 
"This study represents a first-of-its kind look at how urine-based mutation detection can be used to track patients from initial diagnosis through therapy, and then to monitor for early signs of progression," said Dr. Charlie Rodi, chief technology officer at Trovagene. "We are pleased to sponsor this study with MD Anderson, and look forward to learning more about the unique properties and clinical utilities of our transrenal mutation assays."
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.